Abstract B37: Clinical relevance of tumor-infiltrating immune cells in neuroblastoma

O. Melaiu, R. Boldrini, M. Chierici, Cesare Furlanello, D. Fruci
{"title":"Abstract B37: Clinical relevance of tumor-infiltrating immune cells in neuroblastoma","authors":"O. Melaiu, R. Boldrini, M. Chierici, Cesare Furlanello, D. Fruci","doi":"10.1158/2326-6074.TUMIMM17-B37","DOIUrl":null,"url":null,"abstract":"The presence of tumor-infiltrating T cells is crucial for the development of immunotherapies and the prediction of clinical response for many human cancers. Recently, we have shown that tumor-infiltrating T cells have a prognostic value greater than, and independent of, the criteria currently used to stage neuroblastoma, the most common pediatric extra-cranial solid tumor accounting for 15% of childhood cancer-related death. We demonstrated that expression of PD-L1 in tumor cells is inversely correlated with that of HLA class I, and that when combined they represent a promising prognostic biomarker in neuroblastoma. To further dissect the immune heterogeneity of neuroblastoma microenviroment, we evaluated the density of infiltrating dendritic cells (iDC), which are crucial for drug-induced anticancer immune response, in the same cohort of NB samples characterized for type, density, and composition of tumor T lymphocytes and expression of tumor PD-L1 and HLA class I. As for T cells, high density of iDCs was correlated with the presence of infiltrating T cells, expression of tumor HLA class I and favorable clinical outcome, suggesting that iDCs may be critical for robust tumor control by improving prediction of patient survival. Citation Format: Ombretta Melaiu, Renata Boldrini, Marco Chierici, Cesare Furlanello, Doriana Fruci. Clinical relevance of tumor-infiltrating immune cells in neuroblastoma [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2017 Oct 1-4; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2018;6(9 Suppl):Abstract nr B37.","PeriodicalId":92311,"journal":{"name":"Tumor & microenvironment","volume":"3 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumor & microenvironment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2326-6074.TUMIMM17-B37","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The presence of tumor-infiltrating T cells is crucial for the development of immunotherapies and the prediction of clinical response for many human cancers. Recently, we have shown that tumor-infiltrating T cells have a prognostic value greater than, and independent of, the criteria currently used to stage neuroblastoma, the most common pediatric extra-cranial solid tumor accounting for 15% of childhood cancer-related death. We demonstrated that expression of PD-L1 in tumor cells is inversely correlated with that of HLA class I, and that when combined they represent a promising prognostic biomarker in neuroblastoma. To further dissect the immune heterogeneity of neuroblastoma microenviroment, we evaluated the density of infiltrating dendritic cells (iDC), which are crucial for drug-induced anticancer immune response, in the same cohort of NB samples characterized for type, density, and composition of tumor T lymphocytes and expression of tumor PD-L1 and HLA class I. As for T cells, high density of iDCs was correlated with the presence of infiltrating T cells, expression of tumor HLA class I and favorable clinical outcome, suggesting that iDCs may be critical for robust tumor control by improving prediction of patient survival. Citation Format: Ombretta Melaiu, Renata Boldrini, Marco Chierici, Cesare Furlanello, Doriana Fruci. Clinical relevance of tumor-infiltrating immune cells in neuroblastoma [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2017 Oct 1-4; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2018;6(9 Suppl):Abstract nr B37.
B37:肿瘤浸润免疫细胞在神经母细胞瘤中的临床意义
肿瘤浸润T细胞的存在对于许多人类癌症的免疫疗法的发展和临床反应的预测至关重要。最近,我们发现肿瘤浸润性T细胞的预后价值大于且独立于目前用于神经母细胞瘤分期的标准,神经母细胞瘤是最常见的儿童颅外实体瘤,占儿童癌症相关死亡的15%。我们证明了肿瘤细胞中PD-L1的表达与HLA I类的表达呈负相关,并且当它们结合在一起时,它们代表了神经母细胞瘤中有希望的预后生物标志物。为了进一步剖析神经母细胞瘤微环境的免疫异质性,我们评估了浸润性树突状细胞(iDC)的密度,浸润性树突状细胞(iDC)对药物诱导的抗癌免疫反应至关重要,在相同的NB样本队列中,浸润性树突状细胞(iDC)的密度以肿瘤T淋巴细胞的类型、密度和组成以及肿瘤PD-L1和HLA i类的表达为特征。至于T细胞,浸润性树突状细胞的高密度与浸润性T细胞的存在相关。肿瘤HLA I类的表达和良好的临床结果表明,通过改善患者生存预测,iDCs可能对肿瘤控制至关重要。引文格式:Ombretta Melaiu, Renata Boldrini, Marco Chierici, Cesare Furlanello, Doriana frui。肿瘤浸润性免疫细胞在神经母细胞瘤中的临床意义[摘要]。摘自:AACR肿瘤免疫学和免疫治疗特别会议论文集;2017年10月1-4日;波士顿,MA。费城(PA): AACR;癌症免疫学杂志,2018;6(9增刊):摘要nr B37。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信